natgillin/translations-raw huggingface dataset:
In very rare cases, patients receiving Temodal and medicines like it may have a small risk of developing secondary cancers, including leukaemia.
Pri bolnikih, ki prejemajo Temodal in podobna zdravila, lahko obstaja v zelo redkih primerih majhno tveganje za pojav sekundarnih vrst raka, vključno z levkemijo.
In very rare cases, patients taking Temodal and medicines like it may have a small risk of developing secondary cancers, including leukaemia.
Pri bolnikih, ki jemljejo Temodal in podobna zdravila, lahko obstaja v zelo redkih primerih majhno tveganje za pojav sekundarnih vrst raka, vključno z levkemijo.
In very rare cases, patients taking Temomedac and medicines like it may have a small risk of developing secondary cancers, including leukaemia.
Pri bolnikih, ki jemljejo Temomedac in podobna zdravila, lahko obstaja v zelo redkih primerih majhno tveganje za pojav sekundarnih vrst raka, vključno z levkemijo.
In very rare cases, potentially serious or fatal anaphylactoid reactions (similar to severe allergic reactions) may occur following administration of the solution for injection and should be treated symptomatically.
Pri uporabi raztopine za injiciranje se lahko v zelo redkih primerih pojavijo potencialno resne ali smrtne anafilaktične reakcije (podobne hudim alergijskim reakcijam), ki jih je treba zdraviti simptomatsko.
In very rare cases, serious hypersensitivity reactions have been observed which could be fatal.
V zelo redkkih primerih so opazili hude preobčutljivostne reakcije, ki so lahko usodne.
In very rare cases, temporary local reactions occur at the injection site in the form of a normally painless nodule of 0.5 to 1 cm in sheep and of 0.5 to 3 cm in cattle which disappears within 14 days, at the latest.
V zelo redkih primerih se pojavijo začasne lokalne reakcije na mestu injiciranja, običajno v obliki neboleče bule premera 0,5 do 1 cm pri ovcah in 0,5 do 3 cm pri govedu, ki pa izgine najkasneje v 14 dneh.
In very rare cases, temporary local reactions occur at the injection site in the form of a normally painless nodule of 0.5 to 1 cm in sheep and of 0.5 to 3 cm in cattle which disappears within 14 days, at the latest.
V zelo redkih primerih, se pojavijo začasne lokalne reakcije na mestu injiciranja, običajno v obliki neboleče bule premera 0,5 do 1 cm pri ovcah in 0,5 do 3 cm pri govedu, ki pa izgine najkasneje v 14 dneh.
In very rare cases, the use of the veterinary medicinal product has been associated with hearing impairment, usually temporary, and primarily in geriatric dogs.
V zelo redkih primerih je bilo zdravljenje z zdravilom za uporabo v veterinarski medicini povezano z oslabitvijo sluha, ki je bila običajno kratkotrajna in prisotna predvsem pri starejših psih.
In very rare cases, these have progressed to suicidal thoughts and self-endangering behaviour - sometimes after only a single dose of levofloxacin (see section 4.8).
V zelo redkih primerih so se psihotične reakcije stopnjevale vse do pojava samoogrožajočega vedenja in samomorilnih misli – včasih tudi po samo enkratnem odmerku levofloksacina (glejte poglavje 4.8).
In very rare cases, transient lethargy in piglets has been observed.
V zelo redkih primerih so ugotovili pri pujskih prehodno letargijo.
In very rare cases, type-I hypersensitivity reactions (facial swelling, allergic pruritus) have been observed.
V zelo redkih primerih so bile opažene preobčutljivostne reakcije tipa I (zatekanje obraza, alergijski pruritus).
In very rare occasions, abscessation may be observed.
Zelo redko se lahko pojavi abscediranje.
In very small children, the injection may be given into the thigh muscle.
Pri zelo majhnih otrocih se injekcija lahko daje v stegensko mišico.
In view of its action on cellular deoxyribonucleic acid (DNA) 6–mercaptopurine is potentially carcinogenic and consideration should be given to the theoretical risk of carcinogenesis with this treatment.
Ker 6-merkaptopurin deluje na celično deoksiribonukleinsko kislino (DNA), je potencialno kancerogen, pri zdravljenju pa je treba upoštevati tudi možno teoretično tveganje za kancerogenezo.
In view of limited safety and efficacy data in patients with secondary acute myelogenous leukaemia (AML), filgrastim should be administered with caution.
Glede na to, da je podatkov o varnosti in učinkovitosti pri bolnikih s sekundarno akutno mieloično levkemijo malo, je treba filgrastim uporabljati previdno.
In view of the above, it is considered that cutaneous amyloidosis at the injection site should be reflected as an adverse reaction in the product information of Fuzeon.
Glede na zgoraj navedeno se smatra, da mora biti kožna amiloidoza na mestu injiciranja navedena kot neželeni učinek v informacijah o zdravilu zdravila Fuzeon.
In view of the lack of genotoxicity of stiripentol and the well known, special susceptibility of the mouse liver to tumour formation in the presence of hepatic enzyme induction, this finding is not considered to indicate a risk of tumorigenicity in patients.
Glede na odsotnost genotoksičnosti stiripentola in dobro poznane, posebne občutljivosti jeter miši za nastanek tumorjev pri indukciji jetrnih encimov se ta rezultat ne predstavlja povečanega tveganja za pojav tumorjev pri bolnikih.
In view of the long half-life of amiodarone the potential for drug interaction may exist for weeks after discontinuation of amiodarone (see sections 4.2 and 4.4).
Zaradi amiodaronove dolge razpolovne dobe je interakcija možna še tedne po ukinitvi amiodarona (glejte poglavji 4.2 in 4.4).
In view of the MAO inhibitory activity of safinamide, concomitant administration of Xadago and sympathomimetics, such as those present in nasal and oral decongestants or cold medicinal products containing ephedrine or pseudoephedrine, requires caution (see section 4.4).
Zaradi zaviralne aktivnosti safinamida na MAO je pri sočasni uporabi zdravila Xadago in simpatikomimetičnih zdravil, ki so npr. prisotni v nazalnih in peroralnih dekongestivih ali zdravilih proti prehladu, ki vsebujejo efedrin ali psevdoefedrin, potrebna previdnost (glejte poglavje 4.4).
In view of the MAO inhibitory activity of safinamide, the concomitant administration of Xadago and dextromethorphan is not recommended, or if concomitant treatment is necessary, it should be used with caution (see section 4.4).
Zaradi zaviralne aktivnosti safinamida na MAO sočasna uporaba zdravila Xadago in dekstrometorfana ni priporočljiva, če pa je sočasno zdravljenje potrebno, ga je treba izvajati previdno (glejte poglavje 4.4).
In view of the possible risk of microbial contamination, Filgrastim HEXAL syringes are for single use only.
Zaradi možnega tveganja kontaminacije z mikrobi so brizge zdravila Filgrastim HEXAL namenjene le za enkratno uporabo.
In view of the possible risk of microbial contamination, Filgrastim ratiopharm syringes are for single use only.
Ker obstaja tveganje mikrobne kontaminacije so z zdravilom Filgrastim ratiopharm napolnjene brizge namenjene izključno enkratni uporabi.
In view of the possible risk of microbial contamination, Lonquex syringes are for single use only.
Zaradi tveganja mikrobne kontaminacije so z zdravilom Lonquex napolnjene brizge namenjene izključno enkratni uporabi.
In view of the possible risk of microbial contamination, Nivestim syringes are for single use only.
Zaradi tveganja za mikrobiološko kontaminacijo so brizge z zdravilom Nivestim namenjene samo za enkratno uporabo.
In view of the possible risk of microbial contamination, Ratiograstim syringes are for single use only.
Ker obstaja tveganje mikrobne kontaminacije so z zdravilom Ratiofrastim napolnjene brizge namenjene izključno enkratni uporabi.
In view of the possible risk of microbial contamination, Tevagrastim syringes are for single use only.
Ker obstaja tveganje mikrobne kontaminacije so z zdravilom ratiofrastim napolnjene brizge namenjene izključno enkratni uporabi.
In view of the possible risk of microbial contamination, Zarzio syringes are for single use only.
Zaradi možnega tveganja kontaminacije z mikrobi so brizge zdravila Zarzio namenjene le za enkratno uporabo.
In view of the potential impact of bisphosphonates, including zoledronic acid, on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 μmol/l or ≥ 4.5 mg/dl for patients with TIH and ≥ 265 μmol/l or ≥ 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of Zoledronic Acid Teva is not recommended in patients with severe renal impairment.
Glede na možni vpliv zoledronske kisline na delovanje ledvic ob pomanjkanju kliničnih podatkov o varnosti pri bolnikih s težko izhodiščno okvaro ledvic (v kliničnih preskušanjih opredeljeno s serumskim kreatininom ≥ 400 μmol/l ali ≥ 4,5 mg/dl za bolnike s tumorsko povzročeno hiperkalciemijo - TIH - oziroma s serumskim kreatininom ≥ 265 μmol/l ali ≥ 3,0 mg/dl za bolnike z rakom in zasevki v kosteh) in glede na samo omejene farmakokinetične podatke pri bolnikih s težko izhodiščno ledvično okvaro (očistek kreatinina < 30 ml/min), uporabe zdravila Zoledronska kislina Teva pri bolnikih s težko ledvično okvaro ne priporočamo.
In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine 400 µmol/l or 4.5 mg/dl for patients with TIH and 265 µmol/l or 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of zoledronic acid is not recommended in patients with severe renal impairment.
Glede na možni vpliv zoledronske kisline na delovanje ledvic ob pomanjkanju kliničnih podatkov o varnosti pri bolnikih s težko izhodiščno okvaro ledvic (v kliničnih preskušanjih opredeljeno s serumskim kreatininom ≥ 400 μmol/l ali ≥ 4,5 mg/dl za bolnike s tumorsko povzročeno hiperkalciemijo - TIH - oziroma s serumskim kreatininom ≥ 265 μmol/l ali ≥ 3,0 mg/dl za bolnike z rakom in zasevki v kosteh) in glede na samo omejene farmakokinetične podatke pri bolnikih s težko izhodiščno ledvično okvaro (očistek kreatinina < 30 ml/min), uporabe zoledronske kisline pri bolnikih s težko ledvično okvaro ne priporočamo.
In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 μmol/l or
Glede na možni vpliv zoledronske kisline na delovanje ledvic ob pomanjkanju kliničnih podatkov o varnosti pri bolnikih s hudo izhodiščno okvaro ledvic (v kliničnih študijah opredeljeno z vrednostmi serumskega kreatinina ≥ 400 µmol/l ali ≥ 4,5 mg/dl za bolnike s tumorsko povzročeno hiperkalciemijo
In view of the unpredictability of adverse reactions, Oncaspar should be administered only by health care personnel experienced in the use of cancer chemotherapeutic medicinal products.
Zaradi nepredvidljivosti neželenih učinkov lahko zdravilo Oncaspar dajejo le zdravstveni delavci, izkušeni pri uporabi zdravil za kemoterapijo raka.
In ViraferonPeg, the interferon alfa-2b has been ‘pegylated’ (attached to a chemical called polyethylene glycol).
V zdravilu ViraferonPeg je interferon alfa-2b „pegiliran“ (vezan na kemično snov, imenovano polietilenglikol).
In virologically stable treatment-experienced adults, emtricitabine, in combination with an NRTI (either stavudine or zidovudine) and a protease inhibitor (PI) or an NNRTI was shown to be non-inferior to lamivudine with respect to the proportion of responders (< 400 copies/ml) through 48 weeks (77% emtricitabine, 82% lamivudine).
Pri virološko stabilnih odraslih, ki se zdravijo že dalj časa, se emtricitabin, v kombinaciji z NRTI (ali stavudinom ali zidovudinom) in zaviralcem proteaz (PI) ali NNRTI, ni obnesel slabše od lamivudina glede na delež odzivov (< 400 virionov/ml) v obdobju 48 tednov (77 % emtricitabin, 82 % lamivudin).
In virologically suppressed HIV-1 infected patients
Pri bolnikih z virološko supresijo, okuženih z virusom HIV-1
In vitro / in vivo studies indicate that CYP3A4, CYP3A5, and subsequently uridine diphosphate- glucuronosyltransferases (UGT), are involved in the metabolism of isavuconazole.
Študije in vitro / in vivo kaţejo, da so v presnovo izavukonazola vključeni CYP3A4, CYP3A5 in kasneje uridin difosfat-glukuronoziltransferaz (UGT).
In vitro / in vivo studies indicate that CYP3A4, CYP3A5, and subsequently uridine diphosphate- glucuronosyltransferases (UGT), are involved in the metabolism of isavuconazole.
Študije in vitro / in vivo kaţejo, da so v presnovo izavukonazola vključeni CYP3A4, CYP3A5 in kasneje uridin difosfat-glukuronoziltransferaze (UGT).
In vitro activity against clinical isolates has been observed for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., and Histoplasma capsulatum, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 µg/ml.
In vitro so opažali delovanje proti kliničnim izolatom Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp. in Histoplasma capsulatum; večino sevov je zavrla koncentracija vorikonazola v območju od 0,05 do 2 μg/ml.
In vitro activity against clinical isolates has been observed for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., and Histoplasma capsulatum, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 μg/ml.
In vitro so opažali delovanje proti kliničnim izolatom Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp. in Histoplasma capsulatum; večino sevov je zavrla koncentracija vorikonazola v območju od 0,05 do 2 μg/ml.
In vitro activity against clinical isolates has been observed for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., Histoplasma capsulatum, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 μg/ml.
In vitro so opažali delovanje proti kliničnim izolatom Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp. in Histoplasma capsulatum; večino sevov je zavrla koncentracija vorikonazola v območju od 0,05 do 2 µg/ml.
In vitro activity against Dichelobacter nodosus (vir), the bacterial pathogen most commonly associated with infectious pododermatitis (foot rot) in sheep has been demonstrated.
In vitro delovanje proti bakteriji Dichelobacter nodosus (vir), pathogen, ki najbolj pogosto povezan z nalezljivo šepavostjo ovac ni bilo dokazano
In vitro activity against the following pathogens has been shown, but the clinical significance is unknown:
In vitro je bilo dokazano delovanje proti naslednjim patogenom, vendar klinični pomen tega ni znan:
In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP-mediated interactions involving tenofovir alafenamide with other medicinal products is low.
Študije in vitro in klinične farmakokinetične študije medsebojnega delovanja zdravil kažejo, da je možnost interakcij, pri katerih posreduje CYP in vključujejo alafenamidtenofovirat, z drugimi zdravili majhna.
In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP450 mediated interactions involving emtricitabine and tenofovir disoproxil fumarate with other medicinal products is low.
In vitro in klinične študije farmakokinetičnih interakcij so pokazale, da je možnost za s CYP450 posredovane interakcije emtricitabina in dizoproksiltenofovirijevega fumarata z drugimi zdravili majhna.
In vitro and in vivo data in non-target species suggest that the vaccine may provide a degree of cross-protection against L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
Podatki in vitro in in vivo pri neciljnih živalskih vrstah kažejo, da cepivo lahko zagotovi določeno navzkrižno zaščito proti serološki skupini L. interrogans Icterohaemorrhagiae serovar Icterohaemorrhagiae in proti serološki skupini L.kirschneri Grippotyphosa serovar Grippotyphosa.
In vitro and in vivo data in non-target species suggests that the vaccine may provide a degree of cross-protection against L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa.
Podatki in vivo in in vitro pri neciljnih živalskih vrstah kažejo, da cepivo lahko zagotovi določeno navzkrižno zaščito proti serološki skupini L. interrogans Icterohaemorrhagiae serovar Icterohaemorrhagiae in proti serološki skupini L.kirschneri Grippotyphosa serovar Grippotyphosa.
In vitro and in vivo data indicate that axitinib is primarily metabolised by the liver.
In vitro in in vivo podatki kažejo, da se aksitinib presnavlja predvsem v jetrih.
In vitro and in vivo extrapolations indicate that strong and selective inhibitors of CYP1A2 (e.g. enoxacin) have the potential to increase the exposure to pirfenidone by approximately 2 to 4-fold.
In vitro in in vivo ekstrapolacije kažejo, da imajo močni in selektivni zaviralci CYP1A2 (npr. enoksacin) potencial za zvišanje izpostavitve pirfenidonu za približno 2 do 4-krat.
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-l (COX-I).
Raziskave in vitro ter in vivo so pokazale, da meloksikam močneje zavira ciklooksigenazo 2 (COX-2) kot ciklooksigenazo 1 (COX-1).
In vitro and in vivo studies have shown that oestrogens are partially metabolized by cytochrome P450 enzymes, including CYP3A4.
Študije in vitro ter in vivo so pokazale, da se estrogeni delno presnavljajo preko encimov citokroma P450, vključno s CYP3A4.
In vitro and in vivo studies in humans indicate that amifampridine is metabolised to a single major 3- N-acetylated amifampridine metabolite.
Študije in vitro in in vivo pri ljudeh kažejo, da se amifampridin presnavlja v en sam glavni presnovek 3-N-acetiliran amifampridin.
In vitro and in vivo studies to date have not detected any activity of the major metabolite (5-carboxy-pirfenidone), even at concentrations or doses greatly above those associated with activity of pirfenidone itself.
V študijah in vitro in in vivo, ki so bile izvedene do zdaj, niso zaznali nikakršne aktivnosti glavnega presnovka (5-karboksi-pirfenidona), niti pri koncentracijah ali odmerkih, ki so precej presegali tiste, povezane z aktivnostjo samega pirfenidona.
In vitro and in vivo tests did not indicate a genotoxic potential of tacrolimus.
Preizkusi in vitro in in vivo niso pokazali, da bi imel takrolimus genotoksičen potencial.
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 > 45 M) and weak inhibitory effect on the activity of CYP2C19 (IC50 > 20 M) at concentrations that are significantly greater than peak plasma concentrations observed in patients.
Pri in vitro študijah niso ugotovili zaviralnega učinka apiksabana na aktivnost CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 ali CYP3A4 (IC50 > 45 M) in šibek zaviralni učinek na aktivnost CYP2C19 (IC50 > 20 M) pri koncentracijah, ki so bile pomembno večje od največjih plazemskih koncentracij pri človeku.
In vitro assays showed that brivaracetam disposition should not be significantly affected by CYP (eg.
Testi in vitro so pokazali, da naj zaviralci CYP (npr.
In vitro assessment of drug interactions
Ocena interakcij med zdravili in vitro
In vitro binding assays confirmed that ixekizumab does not bind to human Fc receptors I, IIa, and IIIa or to complement component C1q.
Preskusi vezave in vitro so potrdili, da se iksekizumab ne veže na človeške receptorje Fc I, IIa in IIIa ali na komponento komplementa C1q.
In vitro binding of axitinib to human plasma proteins is > 99% with preferential binding to albumin and moderate binding to α1-acid glycoprotein.
In vitro delež vezave aksitiniba na plazemske beljakovine pri ljudeh znaša > 99 %, pri čemer gre v glavnem za vezavo na albumin in zmerno vezavo na α1-kisli glikoprotein.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02 to 200 µg/mL.
In vitro je bila vezava emtricitabina na humane plazemske proteine manj kot <4% in je neodvisna od koncentracije v razponu med 0,02 in 200 µg/ml.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02 – 200 μg/ml.
In vitro je bila vezava emtricitabina na humane plazemske proteine manj kot 4% in je neodvisna od koncentracije v razponu med 0,02 in 200 μg/ml.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/mL.
In vitro je bila vezava emtricitabina na humane plazemske proteine < 4 % in je neodvisna od koncentracije v razponu med 0,02–200 µg/ml.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/ml.
In vitro je bila vezava emtricitabina na humane plazemske proteine manj kot 4 % in je neodvisna od koncentracije v razponu med 0,02 in 200 µg/ml.
In vitro binding of lenvatinib to human plasma proteins is high and ranged from 98% to 99% (0.3 - 30 μg/mL, mesilate).
Vezava lenvatiniba na beljakovine humane plazme in vitro je velika, v razponu od 98 % do 99 % (0,3-30 μg/ml, mesilat).
In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 µg/mL.
In vitro je vezava tenofovirja na humane plazemske proteine < 0,7 % in je neodvisna od koncentracije v razponu med 0,01–25 µg/ml.
In vitro CYP P450 interaction studies
Študije medsebojnega delovanja s CYP P450 in vitro
In vitro daclatasvir is an inhibitor of renal uptake transporters, OAT1 and 3, and OCT2, but is not expected to have a clinical effect on the pharmacokinetics of substrates of these transporters.
Daklatasvir je in vitro zaviralec ledvičnih prenašalcev privzema, OAT1 in 3 ter OCT2, vendar pa kliničnega učinka na farmakokinetiko substratov za te prenašalce ne pričakujemo.
In vitro data also show that olaparib is not a substrate for OATP1B1, OATP1B3, OCT1, BCRP or MRP2 and not an inhibitor of OATP1B3, OAT1 or MRP2.
Podatki in vitro tudi kažejo, da olaparib ni substrat OATP1B1, OATP1B3, OCT1, BCRP ali MRP2 in ni zaviralec OATP1B3, OAT1 ali MRP2.
In vitro data and studies in laboratory animals indicate that 99mTc-depreotide binds with high affinity to somatostatin receptor (SSTR) subtypes 2, 3 and 5.
Podatki in vitro in študije na laboratorijskih živalih kažejo, da se 99mTc-depreotid veže z visoko afiniteto na podtipe 2,3 in 5 somatostatinskih receptorjevg (SSTR).
In vitro data indicate that ambrisentan at 300 μM resulted in less than 50 % inhibition of UGT1A1, UGT1A6, UGT1A9, UGT2B7 (up to 30%) or of cytochrome P450 enzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 (up to 25%).
Podatki in vitro kažejo, da je ambrisentan pri 300 μM povzročil manj kot 50 % zavrtje UGT1A1, UGT1A6, UGT1A9, UGT2B7 (do 30 %) ali encimov citokroma P450 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 in 3A4 (do 25 %).
In vitro data indicate that axitinib is metabolised primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP2C19, and uridine diphosphate-glucuronosyltransferase (UGT) 1A1.
In vitro dobljeni podatki kažejo, da se aksitinib presnavlja predvsem s CYP3A4/5, v manjšem obsegu pa s CYP1A2, CYP2C19 in uridin difosfat-glukuronosiltransferazo (UGT) 1A1.
In vitro data indicate that enzalutamide may be an inhibitor of the efflux transporter P-gp.
Podatki in vitro kažejo, da enzalutamid morda zavira efluksni prenašalec P -gp.
In vitro data indicate that gefitinib is a substrate for the membrane transport protein Pgp.
Podatki in vitro kažejo, da je gefitinib substrat membranske transportne beljakovine Pgp.
In vitro data indicate that inhibition of P-pg and BCRP by abacavir cannot be excluded at intestinal level.
Podatki in vitro kažejo, da zaviranja P-pg in BCRP zaradi abakavirja v prebavilih ni mogoče izključiti.